Evidence map›Paper›PMID 41276717›Full record

ArticleBrain tumor pathology2026

A rare case of supratentorial ependymosarcoma harboring ZFTA::RELA fusion.

Yuji Matsumoto, Yasuki Suruga, Kaishi Satomi, Yohei Inoue, Yasuhiko Hattori, Joji Ishida, Kazuhiko Kurozumi, Sumihito Nobusawa, Junko Hirato, Takehiro Tanaka and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yuji MatsumotoDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.
Yasuki SurugaDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.
Kaishi SatomiDepartment of Pathology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Yohei InoueDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.
Yasuhiko HattoriDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.
Joji IshidaDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.
Kazuhiko KurozumiDepartment of Neurosurgery, Hamamatsu University Hospital, Hamamatsu, Japan.
Sumihito NobusawaDepartment of Human Pathology, Gunma University School of Medicine, Maebashi, Japan.
Junko HiratoDepartment of Pathology, Public Tomioka General Hospital, Tomioka, Japan.
Takehiro TanakaDepartment of Pathology, Okayama University Hospital, Okayama, Japan.
Hiroyuki YanaiDepartment of Pathology, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Okayama, Japan.
Kana WashioDepartment of Pediatrics, Okayama University Hospital, Okayama, Japan.
Koichi IchimuraDepartment of Pathology, Faculty of Medicine, Kyorin University, Tokyo, Japan.
Tomotsugu IchikawaDepartment of Neurosurgery, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Yoshihiro OtaniDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan. yotani@okayama-u.ac.jp.ORCID http://orcid.org/0000-0002-1615-5125
Shota TanakaDepartment of Neurological Surgery, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine, Shikata, Kita-Ku, Okayama, 700-8558, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ependymosarcoma is an exceedingly rare variant of ependymoma characterized by a mixture of ependymomatous and sarcomatous components. We report a case of supratentorial ependymosarcoma harboring a ZFTA::RELA fusion in a 10-year-old girl. Histologically, the tumor comprised an ependymomatous component resembling clear cell ependymoma and a sarcomatous component. ZFTA::RELA fusion was confirmed in both components. Genome-wide methylation profiling classified both components as supratentorial ependymoma, ZFTA fusion-positive by the German Cancer Research Center (DKFZ) CNS tumor classifier v12b8. However, their copy number alteration profiles were distinct. The ependymomatous component exhibited a gain of chromosome 1q and a loss of chromosomes 1p, 9, and 19q, while the sarcomatous component showed a loss of chromosome 14. These findings suggest that both components may have differentiated from a common precursor despite their distinct morphologies. The patient underwent gross total resection followed by adjuvant chemoradiotherapy and remains recurrence-free eight years post-treatment. Further investigation of additional cases is warranted to better understand the pathogenesis of this rare tumor.

Indexed as

EpendymomaGene FusionSupratentorial NeoplasmsChildFemaleHumansOncogene Proteins, FusionTranscription FactorsOncogene Proteins, FusionTranscription FactorsZFTA protein, humanEpendymomaEpendymosarcomaMethylation profilingRELAZFTA

Identifiers

PMID41276717
PMCPMC13375707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.